DURECT Corporation (NASDAQ:DRRX) Scheduled to Post Earnings on Tuesday
DURECT Corporation (NASDAQ:DRRX) is set to release its earnings data after the market closes on Tuesday, August 8th. Analysts expect DURECT Corporation to post earnings of ($0.05) per share for the quarter.
DURECT Corporation (NASDAQ:DRRX) last announced its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $3.60 million. DURECT Corporation had a negative return on equity of 318.49% and a negative net margin of 232.05%. On average, analysts expect DURECT Corporation to post $-0.19 EPS for the current fiscal year and $-0.15 EPS for the next fiscal year.
Shares of DURECT Corporation (NASDAQ DRRX) opened at 1.69 on Friday. The company’s market cap is $239.92 million. The stock’s 50 day moving average price is $1.62 and its 200 day moving average price is $1.19. DURECT Corporation has a one year low of $0.74 and a one year high of $1.95.
Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of DURECT Corporation in a research note on Monday, May 22nd. Stifel Nicolaus upgraded DURECT Corporation from a “hold” rating to a “buy” rating and lifted their price target for the company from $1.25 to $3.00 in a research note on Wednesday, July 12th.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.